The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

August 19, 2017 • By Scott Baltic

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report.

You Might Also Like
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis

Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb), or switched to teriparatide (TPTD). Although bisphosphonates are important in treating osteoporosis, prolonged treatment can attenuate increases in BMD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The women in this cohort had taken bisphosphonates for 40 months, on average. Treatment was maintained or switched according to the women’s preference and their physicians’ discretion. Patients with severe osteoporosis and high disease activity were preferentially switched to TPTD.

The article was published online Aug. 1 in the Journal of Bone and Mineral Metabolism.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At both six and 18 months, the two groups who switched regimens showed significant increases in BMD of the lumbar spine, compared with women who stayed on oral bisphophonates. Those who switched specifically to TPTD also showed a significantly higher 18-month increase in trabecular bone score than did women who remained on bisphosphonates.

Switchers to TPTD showed significantly greater BMD and trabecular bone advantages than did switchers to DMAb.

Switching women with RA from bisphosphonates to DMAb or TPTD “may provide some useful osteoporosis treatment options,” the authors conclude. No previous studies have compared these two switching strategies, they note.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The three groups did not differ significantly in their rates of total fracture during follow-up.

“Many patients are stopping bisphosphonates due to fears of rare side effects, and it is important to have future options that work,” Dr. Kenneth G. Saag, of the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, tells Reuters Health. “Persons with RA have a high risk of osteoporosis leading to fractures, and more proven treatment options are needed.”

The study authors did not reply to requests for additional information.


Reference

  1. Ebina K, Hirao M, Hashimoto J, et al. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab. 2017 Aug 1. doi: 10.1007/s00774-017-0861-4. [Epub ahead of print]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: bisphosphonates, bone mineral density (BMD), Osteoporosis, osteoporosis treatments, Rheumatoid Arthritis (RA), teriparatide, teriparatide treatment for osteoporosis, Women

You Might Also Like:
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.